Besides, tisagenlecleucel, an autologous T cell with a lentiviral vector encoding a CD19-specific CAR, presented a significant efficacy along with a manageable safety profile in a subgroup of Japanese patients with relapsed/refractory (r/r) B-ALL [58] and DLBCL [59], making them a rational treatment strategy in patients with B-ALL and DLBCL. Here, CD19 is linked to diffuse large B-cell lymphoma.